Comorbidities (FTC/TDF vs 3TC/ABC) were common in
our study population, including diabetes (10% vs11%), hyper-
lipidemia (52% vs 62%), and hypertension (33% vs 33%). Ad-
ditionally, 3.2% in both arms had a history of MI. As with
previous studies, we demonstrated lipid beneﬁts when switch-
ing to FTC/TDF [3–6]. Signiﬁcant declines in LDL and
TC were observed by week 12 in the FTC/TDF arm and sig-
niﬁcant reductions in TC, LDL, and TG were seen at week 48.
By NCEP category criteria , higher percentages showed
improvements in TC and LDL, as well as improvement (shift
from a higher risk to a lower risk category) in the predicted
risk for CHD outcomes with FTC/TDF as seen in other com-
parative studies [2, 5]. In an ad hoc analysis, we found that the
predicted Framingham 10-yr Risk Score was more favorable
when switching FTC/TDF; particularly, for those with comor-
bidities, whites, and regimens with a PI other than LPV/r.
Such an improvement in Framingham scores is perhaps one
of the most novel beneﬁts of switching from an 3TC/ABC to
FTC/TDF-containing regimen. It is however, worthwhile to
note that the small number of subjects on LPV/r and other
confounding factors at baseline may make this a weaker corre-
lation and may limit these results from being generalized.
Finally, the changes from baseline in commonly used surro-
gate cardiovascular biomarkers (hsCRP, IL-10, IL -6, TNF-α,
and ﬁbrinogen) between the FTC/TDF and 3TC/ABC arm in a
subset of 159 subjects were not signiﬁcant except a trend toward
signiﬁcance with ﬁbrinogen (P = .062) (Table 5), perhaps with a
larger sample size it may have achieved signiﬁcance.
The SWIFT study showed that high rates of virologic sup-
pression were well maintained through 48 weeks with fewer vi-
rologic failures in subjects who switched to FTC/TDF, and also
this regimen is well tolerated. Decreases in creatinine clearance
did occur with both treatments and were greater in the FTC/
TDF arm. In the FTC/TDF arm, improvements in certain lipid
parameters and in other measures including in NCEP catego-
ries and Framingham predicted risk for CHD outcomes were
noted [15, 16]. In summary, switching patients on a boosted PI
regimen to FTC/TDF from 3TC/ABC is associated with im-
portant metabolic beneﬁts without loss of virologic control.
Supplementary materials are available at Clinical Infectious Diseases online
(http://cid.oxfordjournals.org/). Supplementary materials consist of data
provided by the author that are published to beneﬁt the reader. The
posted materials are not copyedited. The contents of all supplementary
data are the sole responsibility of the authors. Questions or messages
regarding errors should be addressed to the author.
Disclosures. F. B. received travel support to his institution from Me-
tropolis Medical. R. C. received institutional grant support for
participation in the study’s clinical trials. E. D. J. received travel support
through his institution from Gilead. K. H. received institutional grand
support from the Minneapolis Medical Research Foundation and also re-
ceived travel support from Gilead.
Potential conﬂicts of interest. All authors: No reported conﬂicts.
All authors have submitted the ICMJE Form for Disclosure of Potential
Conﬂicts of Interest. Conﬂicts that the editors consider relevant to the
content of the manuscript have been disclosed.
1. Department of Health and Human Services (DHHS). Guidelines for
the use of antiretroviral agents in HIV-1-infected adults and adoles-
cents, 2012. Available at: http://AIDSinfo.nih.gov.
2. Martinez E, Arranz JA, Podzamczer D, et al. Efﬁcacy and safety of
NRTI’s switch to tenofovir plus emtricitabine (Truvada) vs abacavir
plus lamivudine (Kivexa) in patients with virologic suppression receiv-
ing a lamivudine containing HAART: The BICOMBO study [oral pre-
sentation]. Paper presented at: 4th International AIDS Society
Conference on HIV Pathogenesis, Treatment, and Prevention (IAS).
Sydney, Australia, July 22–26, 2007.
3. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus teno-
fovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;
4. Valantin MA, Bittar R, de Truchis P, et al. Switching the nucleoside
reverse transcriptase inhibitor backbone to tenofovir disoproxil
fumarate + emtricitabine promptly improves triglycerides and low-
density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob
Chemother 2010; 65:556–61.
5. Behrens G, Maserati R, Rieger A, et al. Switching from kivexa [ABC/
3TC ]+kaletra [LPV/r] to truvada [TDF/FTC]+kaletra [LPV/r]
reduces high hholesterol: results of a 12 week randomized, controlled
study (ROCKET II) [Poster WEPE0110]. Poster presented at: XVIII
International AIDS Conference. Vienna, Austria, July 18–23, 2010.
6. Moyle G, Orkin C, Fisher M, et al. Switc hing from kivexa (KVX) +
efavirenz (EFV) to atripla (ATR) reduces total cholesterol in hyper-
cholesterolemic subjects: ﬁnal results of a 24-week, andomised study
[poster P80]. Poster presented at: 10th International Congress on
Drug Therapy in HIV Infection. Glasgow, UK, November 7–11, 2010.
7. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in
patients with HIV infection exposed to speciﬁc individual antiretrovi-
ral drugs from the 3 major drug classes: the data collection on adverse
events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201:
8. SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside
reverse transcriptase inhibitors and risk of myocardial infarction in
HIV-infected patients. AIDS 2008; 22:F17–24.
9. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretro-
viral drugs on the risk of myocardial infarction in human immunode-
ﬁciency virus-infected patients: a case-control study nested within the
French Hospital Database on HIV ANRS cohort CO4. Arch Intern
Med 2010; 170:1228–38.
10. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Relation
between use of nucleosidic reverse transcriptase inhibitors (NRTI) and
risk of acute myocardial infarction (AMI): a nested case control study
using Quebec’s public health insurance database (RAMQ)[ poster].
Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treat-
ment, and Prevention. Cape Town, South Africa, July 19–22, 2009.
11. Bedimo R, Westfall A, Drechsler H, Vidiella G, Tebas P. Abacaviruse
and risk of acute myocardial infarction and cerebrovascular disease in
the HAART era [oral presentation]. Paper presented at: 5th IAS Con-
ference on HIV Pathogenesis, Treatment and Prevention. Cape Town,
South Africa, July 19–22, 2009
12. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Associa-
tion of immunologic and virologic factors with myocardial infarction
CID 2013:56 (1 June)